Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD22+ Relapsed/Refractory B-ALL”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Early research (Phase 1)Study completedNCT00889408
What this trial is testing

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Who this might be right for
LeukemiaLymphoma
Masonic Cancer Center, University of Minnesota 25
Early research (Phase 1)Ended earlyNCT02588456
What this trial is testing

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
University of Pennsylvania 5
Early research (Phase 1)Looking for participantsNCT06208735
What this trial is testing

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Who this might be right for
B-Cell LeukemiaNon-Hodgkin's LymphomaB-cell Acute Lymphoblastic Leukemia+5 more
British Columbia Cancer Agency 24
Testing effectiveness (Phase 2)UnknownNCT04723901
What this trial is testing

Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Dual-target CAR-T CellsB ALLRelapse+1 more
Shenzhen University General Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Very early researchUnknownNCT03407859
What this trial is testing

Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL

Who this might be right for
Therapy Related Leukemia
Zhujiang Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT04150497
What this trial is testing

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Cellectis S.A. 52
Early research (Phase 1)Looking for participantsNCT06326008
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in Relapse
Beijing GoBroad Hospital 48
Testing effectiveness (Phase 2)Ended earlyNCT03698552
What this trial is testing

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Blasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive+2 more
M.D. Anderson Cancer Center 37
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Testing effectiveness (Phase 2)Study completedNCT01219816
What this trial is testing

Multi-centric Study

Who this might be right for
B ALLCD22+ ExpressionRefractory B-ALL
Nantes University Hospital 57
Early research (Phase 1)Looking for participantsNCT05010564
What this trial is testing

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Who this might be right for
Leukemia, B-Cell
Baylor College of Medicine 38
Testing effectiveness (Phase 2)Looking for participantsNCT06735495
What this trial is testing

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT02981628
What this trial is testing

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic Leukemia+1 more
Children's Oncology Group 80
Testing effectiveness (Phase 2)WithdrawnNCT02844530
What this trial is testing

Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL

Who this might be right for
CD22+ Relapsed/Refractory B-ALL
Nantes University Hospital
Early research (Phase 1)UnknownNCT04007978
What this trial is testing

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

Who this might be right for
B Cell LymphomaAcute Lymphoblastic Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 50
Testing effectiveness (Phase 2)Looking for participantsNCT06880913
What this trial is testing

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Who this might be right for
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital 50
Early research (Phase 1)Ended earlyNCT04508842
What this trial is testing

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

Who this might be right for
Refractory and Relapsed B Cell Acute Leukemia
Hebei Yanda Ludaopei Hospital 2
Testing effectiveness (Phase 2)UnknownNCT05429905
What this trial is testing

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Who this might be right for
Lymphoblastic LeukemiaLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Leukemia in Children+2 more
KK Women's and Children's Hospital 48
Next Page